{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:51Z","timestamp":1788265191964,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02981-7","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:59:44Z","timestamp":1763135984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study"],"prefix":"10.1186","volume":"22","author":[{"given":"Wenyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangbing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiurong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"10161","key":"2981_CR1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"W-K Seto","year":"2018","unstructured":"Seto W-K, Lo Y-R, Pawlotsky J-M, Yuen M-F. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313\u201324.","journal-title":"Lancet"},{"key":"2981_CR2","doi-asserted-by":"crossref","unstructured":"Hu K, Zai W, Xu M, Wang H, Song X, Huang C, et al. Augmented epigenetic repression of hepatitis B virus covalently closed circular DNA by interferon-\u03b1 and small-interfering RNA synergy. mBio. 2024;15 (12):e0241524","DOI":"10.1128\/mbio.02415-24"},{"key":"2981_CR3","first-page":"2021","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact","author":"World Health O","year":"2021","unstructured":"World Health O. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact. Geneva: World Health Organization; 2021. p. 2021."},{"issue":"2","key":"2981_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3350\/cmh.2023.0412","volume":"30","author":"S Shan","year":"2024","unstructured":"Shan S, Zhao X, Jia J. Comprehensive approach to controlling chronic hepatitis B in China. Clin Mol Hepatol. 2024;30(2):135\u201343.","journal-title":"Clin Mol Hepatol"},{"issue":"10381","key":"2981_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"W-J Jeng","year":"2023","unstructured":"Jeng W-J, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039\u201352.","journal-title":"Lancet"},{"issue":"2","key":"2981_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","volume":"66","author":"JH Kim","year":"2017","unstructured":"Kim JH, Sinn DH, Kang W, Gwak G-Y, Paik Y-H, Choi MS, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66(2):335\u201343.","journal-title":"Hepatology"},{"issue":"7","key":"2981_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/liv.14482","volume":"40","author":"E Ogawa","year":"2020","unstructured":"Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40(7):1578\u201389.","journal-title":"Liver Int"},{"issue":"6","key":"2981_CR8","first-page":"850","volume":"9","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Peng H, Liu X, Wang H, Du J, Luo X, et al. Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease. J Clin Transl Hepatol. 2021;9(6):850\u20139.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"2981_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis. 2018;12(1):33\u20134.","journal-title":"Clin Liver Dis"},{"issue":"11","key":"2981_CR10","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","volume":"18","author":"Y Sun","year":"2020","unstructured":"Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, et al. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clin Gastroenterol Hepatol. 2020;18(11):2582\u201391.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2981_CR11","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jhep.2022.07.018","volume":"77","author":"D Ji","year":"2022","unstructured":"Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang J-B, et al. Entecavir plus Biejia-ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol. 2022;77(6):1515\u201324.","journal-title":"J Hepatol"},{"issue":"12","key":"2981_CR12","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","volume":"64","author":"M Nassal","year":"2015","unstructured":"Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972\u201384.","journal-title":"Gut"},{"key":"2981_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105892","volume":"226","author":"S Jiang","year":"2024","unstructured":"Jiang S, Guo S, Huang Y, Xu J, Li Y, Zeng Y, et al. Interim analysis of the PARADISE study: benefits of add-on peginterferon-\u03b1 in NA-treated patients with CHB. Antiviral Res. 2024;226:105892.","journal-title":"Antiviral Res"},{"key":"2981_CR14","doi-asserted-by":"crossref","unstructured":"Lin C, Huang Y, Ran N, Liu J, Luo L, Zhang X, et al. Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-\u03b1. Gut. 2025.","DOI":"10.1136\/gutjnl-2025-334813"},{"issue":"6","key":"2981_CR15","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201949568","volume":"22","author":"D Stadler","year":"2021","unstructured":"Stadler D, K\u00e4chele M, Jones AN, Hess J, Urban C, Schneider J, et al. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep. 2021;22(6):e49568.","journal-title":"EMBO Rep"},{"issue":"8","key":"2981_CR16","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/jgh.14986","volume":"35","author":"YK Park","year":"2020","unstructured":"Park YK, Lee SY, Lee AR, Kim K-C, Kim K, Kim K-H, et al. Antiviral activity of interferon-stimulated gene 20, as a putative repressor binding to hepatitis B virus enhancer II and core promoter. J Gastroenterol Hepatol. 2020;35(8):1426\u201336.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2981_CR17","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41401-021-00765-7","volume":"43","author":"L-N Zhao","year":"2021","unstructured":"Zhao L-N, Yuan H-F, Wang Y-F, Yun H-L, Zheng W, Yuan Y, et al. IFN-\u03b1 inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver. Acta Pharmacol Sin. 2021;43(6):1484\u201394.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"2981_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/infdis\/jiz143","volume":"220","author":"JH Bockmann","year":"2019","unstructured":"Bockmann JH, Stadler D, Xia Y, Ko C, Wettengel JM, Schulze Zur Wiesch J, et al. Comparative analysis of the antiviral effects mediated by type I and III interferons in Hepatitis B virus-infected hepatocytes. J Infect Dis. 2019;220(4):567\u201377.","journal-title":"J Infect Dis"},{"issue":"12","key":"2981_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jiac.2020.07.005","volume":"26","author":"M Bahardoust","year":"2020","unstructured":"Bahardoust M, Mokhtare M, Barati M, Bagheri-Hosseinabadi Z, Karimi Behnagh A, Keyvani H, et al. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: a 48-week follow-up study. J Infect Chemother. 2020;26(12):1265\u201371.","journal-title":"J Infect Chemother"},{"key":"2981_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121778","volume":"14","author":"W-X Wang","year":"2023","unstructured":"Wang W-X, Jia R, Jin X-Y, Li X, Zhou S-N, Zhang X-N, et al. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-\u03b1 in NAs-suppressed chronic hepatitis B patients. Front Immunol. 2023;14:1121778.","journal-title":"Front Immunol"},{"key":"2981_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779347","volume":"12","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, et al. Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive HBsAg carriers: a meta-analysis. Front Immunol. 2021;12:779347.","journal-title":"Front Immunol"},{"issue":"23","key":"2981_CR22","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1097\/CM9.0000000000001793","volume":"134","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Cai D-C, Hu P, Ren H. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl). 2021;134(23):2810\u20137.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"2981_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/jgh.16357","volume":"39","author":"H Chen","year":"2024","unstructured":"Chen H, Fu J-J, Li L, Wang X, Pan X-C. Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study. J Gastroenterol Hepatol. 2024;39(1):180\u20134.","journal-title":"J Gastroenterol Hepatol"},{"key":"2981_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1413589","volume":"14","author":"Z-B Li","year":"2024","unstructured":"Li Z-B, Chen D-D, Jia Y-F, He Q-J, Cui L, Du F-X, et al. Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment. Front Cell Infect Microbiol. 2024;14:1413589.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"2981_CR25","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1365-2036.2012.05098.x","volume":"35","author":"GLH Wong","year":"2012","unstructured":"Wong GLH, Wong VWS, Chan HY, Tse PCH, Wong J, Chim AML, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther. 2012;35(11):1326\u201335.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2981_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5152\/tjg.2023.21978","volume":"34","author":"J Han","year":"2023","unstructured":"Han J, Guo Y, Zhang X, Zhang Y, Sun J, He J, et al. Prevalence and associated factors of low-level viremia in chronic hepatitis B patients after long-term therapy with nucleos(t)ide analogs. Turk J Gastroenterol. 2023;34(1):53\u201361.","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"2981_CR27","first-page":"42","volume":"31","author":"T Li","year":"2023","unstructured":"Li T, Kong Y, Liu YY, Liu TF, Ma AD, Li LQ, et al. Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia\u202f: a single-center retrospective cross-sectional study. Zhonghua Gan Zang Bing Za Zhi. 2023;31(1):42\u20138.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"6","key":"2981_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/v9060156","volume":"9","author":"L Allweiss","year":"2017","unstructured":"Allweiss L, Dandri M. The role of cccDNA in HBV maintenance. Viruses. 2017;9(6):156.","journal-title":"Viruses"},{"issue":"2","key":"2981_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","volume":"66","author":"C-L Lai","year":"2017","unstructured":"Lai C-L, Wong D, Ip P, Kopaniszen M, Seto W-K, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66(2):275\u201381.","journal-title":"J Hepatol"},{"issue":"1","key":"2981_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-019-0891-4","volume":"14","author":"Y-T Lan","year":"2019","unstructured":"Lan Y-T, Wang Z-L, Tian P, Gong X-N, Fan Y-C, Wang K. Treg\/Th17 imbalance and its clinical significance in patients with hepatitis B-associated liver cirrhosis. Diagn Pathol. 2019;14(1):114.","journal-title":"Diagn Pathol"},{"issue":"30","key":"2981_CR31","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.3748\/wjg.v17.i30.3526","volume":"17","author":"DH Sinn","year":"2011","unstructured":"Sinn DH, Lee HI, Gwak G-Y, Choi MS, Koh KC, Paik SW, et al. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol. 2011;17(30):3526\u201330.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2981_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3350\/cmh.2020.0012","volume":"26","author":"SB Lee","year":"2020","unstructured":"Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang S-J, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol. 2020;26(3):364\u201375.","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"2981_CR33","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1111\/jgh.14750","volume":"34","author":"T-S Kim","year":"2019","unstructured":"Kim T-S, Sinn DH, Kang W, Gwak G-Y, Paik Y-H, Choi MS, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. J Gastroenterol Hepatol. 2019;34(11):2028\u201335.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2981_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59985-8","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Sun W, Xu X, Jiang Q, Shi Y, Zhang H, et al. Hepatitis B virus surface antigen drives T cell immunity through non-canonical antigen presentation in mice. Nat Commun. 2025;16(1):4591.","journal-title":"Nat Commun"},{"issue":"6","key":"2981_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249\u201362.","journal-title":"J Hepatol"},{"issue":"8","key":"2981_CR36","first-page":"2125","volume":"19","author":"M Makvandi","year":"2018","unstructured":"Makvandi M, Soleimani Jelodar R, Samarbafzadeh A, Neisi N, Sharifi Z, Gholampour A, et al. Natural history of chronic hepatitis B virus infection in Ahvaz City. Iran. Asian Pac J Cancer Prev. 2018;19(8):2125\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2981_CR37","doi-asserted-by":"crossref","unstructured":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2) 370 98.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"2981_CR38","unstructured":"[Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]. Zhonghua Gan Zang Bing Za Zhi. 2022;30(12) 1309 31."},{"issue":"6","key":"2981_CR39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","volume":"41","author":"Z-B Li","year":"2021","unstructured":"Li Z-B, Li L, Niu X-X, Chen S-H, Fu Y-M, Wang C-Y, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int. 2021;41(6):1254\u201364.","journal-title":"Liver Int"},{"issue":"S1","key":"2981_CR40","first-page":"14","volume":"32","author":"CR Song","year":"2024","unstructured":"Song CR, Li YJ, Li LQ, Chen EQ. Switching to TMF rescue therapy in patients developing low-level viremia with ETV or TAF treatment. Zhonghua Gan Zang Bing Za Zhi. 2024;32(S1):14\u20138.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"8","key":"2981_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3748\/wjg.v27.i8.666","volume":"27","author":"G-Q Yin","year":"2021","unstructured":"Yin G-Q, Li J, Zhong B, Yang Y-F, Wang M-R. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol. 2021;27(8):666\u201376.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2981_CR42","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-024-10648-8","volume":"18","author":"S Jiang","year":"2024","unstructured":"Jiang S, Guo S, Huang Y, Yin Y, Feng J, Zhou H, et al. Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-\u03b1: a systematic review and meta-analysis. Hepatol Int. 2024;18(3):892\u2013903.","journal-title":"Hepatol Int"},{"key":"2981_CR43","doi-asserted-by":"publisher","first-page":"S844","DOI":"10.1016\/S0168-8278(22)01984-5","volume":"77","author":"X-Y Chen","year":"2022","unstructured":"Chen X-Y, Ren S, Lu J, Ma L, Zheng S, Hu Z. SAT382 - Combination therapy in HBeAg-negative chronic hepatitis B patients with low-level viremia to nucleos (tide) analogues. J Hepatol. 2022;77:S844.","journal-title":"J Hepatol"},{"key":"2981_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2516173","author":"X Wang","year":"2025","unstructured":"Wang X, Lai C, Li R, Lei J, Xie Y, Li Z, et al. High HBsAg clearance rate and viral dynamics in HBeAg-positive. ALT-normal children and adolescents with chronic HBV infection: results from the prospective sprout project. Emerg Microbes Infect. 2025. https:\/\/doi.org\/10.1080\/22221751.2025.2516173.","journal-title":"Emerg Microbes Infect"},{"key":"2981_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1474342","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yang X, Tan L, Tian Y, Zhao Z, Ru S. The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1474342.","journal-title":"Front Pharmacol"},{"key":"2981_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106192","volume":"240","author":"Q Hu","year":"2025","unstructured":"Hu Q, Zhang X, Cao X, Tao S, Chen C, Lu M, et al. Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients. Antivir Res. 2025;240:106192.","journal-title":"Antivir Res"},{"key":"2981_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.893512","volume":"13","author":"S Wu","year":"2022","unstructured":"Wu S, Yi W, Gao Y, Deng W, Bi X, Lin Y, et al. Immune mechanisms underlying hepatitis B surface antigen seroclearance in chronic hepatitis B patients with viral coinfection. Front Immunol. 2022;13:893512.","journal-title":"Front Immunol"},{"issue":"17","key":"2981_CR48","doi-asserted-by":"publisher","first-page":"e00442","DOI":"10.1128\/JVI.00442-20","volume":"94","author":"J Cheng","year":"2020","unstructured":"Cheng J, Zhao Q, Zhou Y, Tang L, Sheraz M, Chang J, et al. Interferon Alpha Induces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcription. J Virology. 2020;94(17):e00442\u201320.","journal-title":"J Virology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02981-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02981-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02981-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:04:31Z","timestamp":1763168671000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02981-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2981"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02981-7","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted approval by the Ethics Committee of Tongji Hospital (TJ-IRB20220929) of Huazhong University of Science and Technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"375"}}